Tuesday, March 11, 2025 | 11:07 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Aurobindo Pharma receives final approval for Dexmedetomidine Hydrochloride Injection

Image

Capital Market

From USFDA

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride Injection, 200 mcg (base)/2 mL (100 mcg (base)/mL) single-dose vials. The product is to be launched post Q1 FY16-17.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Precedex Injection, 200 mcg/2 mL, of Hospira, Inc.

Dexmedetomidine Hydrochloride Injection is used as a sedation of non-intubated patients prior to and/or during surgical and other procedures. The approved product has an estimated market size of $59.1 million for the twelve months ending January 2016 according to IMS.

 

Powered by Capital Market - Live News

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 18 2016 | 11:43 AM IST

Explore News